HAUPT, ANDREAS,LANGE, UDO,BRAJE, WILFRIED,TURNER, SEAN COLM,GENESTE, HERVE,DRESCHER, KARLA,UNGER, LILIANE,JONGEN-RELO, ANA LUCIA,BESPALOV, ANTON
申请号：
NZ58505108
公开号：
NZ585051A
申请日:
2008.10.31
申请国别(地区):
NZ
年份:
2012
代理人:
摘要：
Disclosed is a 1,2,4-triazin-3,5-dione compound, the physiologically tolerated salts, the tautomers and the N-oxides of formula I, wherein: A is a saturated or unsaturated hydrocarbon chain having a chain length of 4 to 6 carbon atoms, the hydrocarbon chain being unsubstituted or substituted by 1, 2 or 3 methyl groups R1 is selected from the group consisting of hydrogen, C1-C3 alkyl and fluorinated C1-C3 alkyl R2 is hydrogen, halogen, cyano, C1-C3 alkyl, C1-C3 alkoxy, fluorinated C1-C3 alkyl or fluorinated C1-C3 alkoxy R3 is selected from the group consisting of branched C4-C6 alkyl and C3-C6 cycloalkyl, and R4 is C1-C3 alkyl, C3-C6 cycloalkyl, fluorinated C1-C3 alky and fluorinated C3-C6 cycloalkyl. An example of a compound of formula I is 2-{ 4-[4-(2-tert-Butyl-6-trifluoromethyl-pyrimidin-4-yl)-piperazin-l-yl]-butyl} -2H-[1 ,2,4]triazine-3,5-dione. Further disclosed is a pharmaceutical composition comprising at least one compound of formula I, and the use of a therapeutically effective amount of a compound of formula I for the manufacture of a medicament for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand, such as schizophrenia, bipolar disorder, drug addiction, diabetic nephropathy.
